Scott Tarriff
CIK 1469124 · CEO · last filed 2024-03-01
Scott Tarriff is a CEO who has filed 59 SEC Form 4 insider transactions across 4 companies since 2009. The most recent filing shows the insider had shares withheld for taxes covering $13.3K of EGRX on Mar 1, 2024. Across all open-market trades the lifetime net is −$24.4M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EGRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MAHWAH, NJ 07430
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | CEO | 1,453,244 | $2.14 | $3.11M | -$24.37M | 37 | 2024-03-01 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 4,186 | $0.87 | $3.6K | $0 | 6 | 2020-01-03 |
| Theriva Biologics, Inc. (SYN) Delisted | Director | 30,000 | $1.02 | $30.6K | $0 | 8 | 2019-12-06 |
| CLINICAL DATA INC (CLDA) Delisted | Director | 0 | — | — | $0 | 3 | 2011-04-14 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-01 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Tax (F) | −2,119 | -$13.3K | EDGAR |
| 2024-02-29 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Mixed | +9,796 | -$20.3K | EDGAR |
| 2024-01-09 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Tax (F) | −4,322 | -$22.2K | EDGAR |
| 2023-11-03 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −21,619 | -$299.3K | EDGAR |
| 2023-11-02 | — | Notice (144) | −10,694 | -$150.0K | EDGAR |
| 2023-11-01 | — | Notice (144) | −10,925 | -$150.0K | EDGAR |
| 2023-10-04 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −20,245 | -$300.0K | EDGAR |
| 2023-10-03 | — | Notice (144) | −10,734 | -$155.0K | EDGAR |
| 2023-10-02 | — | Notice (144) | −9,511 | -$150.0K | EDGAR |
| 2023-05-18 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Sell (S) | −15,000 | -$299.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.